275 related articles for article (PubMed ID: 32487595)
1. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
[TBL] [Abstract][Full Text] [Related]
2. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
[TBL] [Abstract][Full Text] [Related]
3. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
5. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
6. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
[No Abstract] [Full Text] [Related]
8. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
Demols A; Bucalau AM; Mans L
Curr Opin Oncol; 2022 Jul; 34(4):403-411. PubMed ID: 35837710
[TBL] [Abstract][Full Text] [Related]
9. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
10. Continuum of care for advanced biliary tract cancers.
Vienot A; Neuzillet C
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):810-824. PubMed ID: 32586782
[TBL] [Abstract][Full Text] [Related]
11. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Kim BJ; Yoo C; Kim KP; Hyung J; Park SJ; Ryoo BY; Chang HM
Br J Cancer; 2017 Feb; 116(5):561-567. PubMed ID: 28081540
[TBL] [Abstract][Full Text] [Related]
13. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
Ying J; Chen J
Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
[TBL] [Abstract][Full Text] [Related]
14. Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair.
Lamarca A; Barriuso J; McNamara MG; Valle JW
Cancer Treat Rev; 2018 Nov; 70():168-177. PubMed ID: 30218788
[TBL] [Abstract][Full Text] [Related]
15. Current status of chemotherapy for the treatment of advanced biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Koike K
Korean J Intern Med; 2013 Sep; 28(5):515-24. PubMed ID: 24009445
[TBL] [Abstract][Full Text] [Related]
16. Second-line therapies in advanced biliary tract cancers.
Tella SH; Kommalapati A; Borad MJ; Mahipal A
Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
[TBL] [Abstract][Full Text] [Related]
17. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment options for advanced biliary tract carcinoma.
Xie C; McGrath NA; Monge Bonilla C; Fu J
J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
[TBL] [Abstract][Full Text] [Related]
19. New Horizons for Precision Medicine in Biliary Tract Cancers.
Valle JW; Lamarca A; Goyal L; Barriuso J; Zhu AX
Cancer Discov; 2017 Sep; 7(9):943-962. PubMed ID: 28818953
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of biliary tract cancers.
Uson Junior PLS; Bogenberger J; Borad MJ
Curr Opin Gastroenterol; 2020 Mar; 36(2):85-89. PubMed ID: 31972599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
